Pharmaceutical Executive September 22, 2025
Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.
Pharmaceutical Executive: How was the transition from COO to CEO?
Ryan Quigley: The transition has been very smooth. I’ve worked at Inizio for the last four-to-five years. Our former CEO will continue as part of the board. We’ve been working on the transition for a period of time and we’re confident that it’s moving in the right direction.
I don’t know if it’s always the case, it’s been great that we’ve been able to work together. He’s one of the founders and helped build out the company and I was part of the journey with him. It’s been very useful that he’s staying on....
Today's Sponsors
Today's Sponsor